Monday, November 18, 2024
- 10:30AM-12:30PM
-
Abstract Number: 2325
Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2322
Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2439
Preliminary Analysis of Open-Label Dose-Titration Phase of SLE Treatment with N-Acetylcysteine (SNAC) Shows Evidence for Potential Improvement of SLEDAI, BILAG, ADHD and Fatigue Scores in Patients with Active SLE
SLE – Treatment Poster III- 10:30AM-12:30PM
-
Abstract Number: 2170
Preliminary Evaluation of a Patient-Reported Version for the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI): The Systemic Lupus Erythematosus Disease Activity Questionnaire (SLEDAQ)
Patient Outcomes, Preferences, & Attitudes Poster III- 10:30AM-12:30PM
-
Abstract Number: 2053
Presence of ANA to Development of Rheumatic Diseases
Miscellaneous Rheumatic & Inflammatory Diseases Poster III- 10:30AM-12:30PM
-
Abstract Number: 2205
Presence of Nailfold Capillary Changes Correlates with More Severe Organ Involvement in Juvenile Systemic Scleroderma. Results of the Juvenile Scleroderma Inception Cohort
Pediatric Rheumatology – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 2461
Prevalence and Impact of Peripheral Neuropathy in SSc: A Frequent and Disabling Manifestation in SSc, and a Potential Surrogate Marker for Autonomic Neuropathy
Systemic Sclerosis & Related Disorders – Clinical Poster III- 10:30AM-12:30PM
-
Abstract Number: 2520
Prevalence and Incidence of Giant Cell Arteritis Among Medicare Fee-For-Service Beneficiaries: United States, 2014–2019
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III- 10:30AM-12:30PM
-
Abstract Number: 2321
Prevalence and Risk Factors of Metabolic Dysfunction-associated Steatotic Liver Disease
SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster III- 10:30AM-12:30PM
-
Abstract Number: 1889
Prevalence of Physician-Diagnosed versus Clinically Confirmed Primary Sjögren’s Syndrome (SS) Among Adults in the United States
Epidemiology & Public Health Poster III- 10:30AM-12:30PM
-
Abstract Number: 1879
Prevalence of Relapsing Polychondritis in Colombia: Data from the National Health Registry 2018 – 2023
Epidemiology & Public Health Poster III- 10:30AM-12:30PM
-
Abstract Number: 2090
Prevalence of Steatotic Liver Disease and Liver Fibrosis Among Patients with Osteoarthritis (OA)
Osteoarthritis – Clinical Poster II- 10:30AM-12:30PM
-
Abstract Number: 2147
Primary and Secondary Prevention of Osteoporotic Fracture in the Elderly Patients